Towa International Will Start Marketing in Libya with Medica

Towa International arrives in Africa. The pharmaceutical multinational has announced the formalization of a strategic agreement with Medica, one of the main pharmaceutical companies in Libya, in order to begin marketing its medicines in this country, the company announced in a statement.

The pharmaceutical holding company Towa specializing in the research, development, manufacturing, marketing and distribution of medicines has received certification for the manufacture of non-sterile solid medicines and their distribution in Libya.

The certification obtained is valid for five years, “which guarantees a stable and long-term framework for cooperation with Medica,” the company explained. Towa International will market its products through its subsidiaries in Spain, Italy and Portugal.

Martorelles, the facilities in Barcelona will be the ones that will produce the medicines Towa International will sell in Libya

“Our priority is to ensure that all patients in Libya have access to high-quality treatments; this certification opens up new business opportunities in a key market such as Libya,” said João Paulo Nascimento, Towa International’s European commercial director, in the statement.

The Martorelles plant, one of the largest in Europe with more than 35,000 square metres, is responsible for producing medicines for the North African market.

Recently, the Japanese pharmaceutical holding company announced the expansion of said plant with a new high containment area designed to manage the production of highly potent substances with an investment of more than nine million euros.

Towa is an international operator specializing in the research, development, manufacturing, marketing and distribution of generic and value-added medicines, which it distributes directly in Europe and the United States through its commercial subsidiaries, Towa Pharmaceutical and Breckenridge Pharmaceutical, and in more than thirty countries through its business unit Towa2B.

__

(Featured image by jorono via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce. A third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us